HassanMFathallah-ShaykhMDPh.D

Neurooncology

Professor of Neurology, Mathematics, Engineering, and Developmental and Cell Biology

Overview of Dr. Fathallah-Shaykh

Dr. Hassan Fathallah-Shaykh is a neurologist in Birmingham, AL and is affiliated with multiple hospitals in the area, including University of Alabama Hospital and UAB Highlands. He received his medical degree from American University of Beirut Faculty of Medicine and has been in practice 32 years. Dr. Fathallah-Shaykh accepts several types of health insurance, listed below. He is one of 18 doctors at UAB Highlands and one of 132 doctors at University of Alabama Hospital who specialize in Neurology. He has more than 50 publications and over 500 citings.

Office
619 19th St S
Birmingham, AL 35233
Book by Phone+1(659) 734-1582

Education & Training

University of Illinois at ChicagoPh.D., Mathematics, Phi Kappa Phi, 2005 - 2007
New York Presbyterian Hospital (Cornell Campus)Residency, Neurology, 1990 - 1993
Duke University HospitalResidency, Internal Medicine, 1989 - 1990
University of ChicagoResidency, Neurology, 1986 - 1989
American University of Beirut Faculty of MedicineClass of 1985

Certifications & Licensure

CA State Medical License 2006 - 2025
AL State Medical License 2008 - 2024
IL State Medical License 1986 - 2011
TX State Medical License 1993 - 2011
American Board of Psychiatry and Neurology Neurology
Neuro-Oncology

Clinical Trials

Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM) Start of enrollment: 2009 Jun 01
Completed
Phase 3

Publications & Presentations

PubMed

16 citations
c-Src and neural Wiskott-Aldrich syndrome protein (N-WASP) promote low oxygen-induced accelerated brain invasion by gliomas.
Zhuo Tang, Lita M. Araysi, Hassan M. Fathallah-Shaykh
Plos One. 2013-09-19
29 citations
Priming in the brain, an immunologically privileged organ, elicits anti-tumor immunity.
Hassan M. Fathallah-Shaykh, Wei Gao, Michael Cho, Maria Alejandra Herrera
International Journal of Cancer. 1998-01-19
60 citations
Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma
Patrick Y. Wen, Antonio Omuro, Manmeet Ahluwalia, Hassan M. Fathallah-Shaykh, Nimish Mohile
Neuro-Oncology. 2015-09-01

Press Mentions

Rowan Innovations: Moving Great Ideas from the Lab to the MarketplaceAugust 9th, 2021
JAMA NeurologyJuly 11th, 2016
Proteins Identified That May Help Brain Tumors SpreadSeptember 20th, 2013

Grant Support

Tumor Antigen Presentation By MicrogliaNational Cancer Institute2000–2002
Prephase I Gene/Immune Therapy Of Malignant Brain TumorNational Cancer Institute2000–2001
Prephase I Gene/Immune Therapy Of Malignant Brain TumorNational Cancer Institute1999–2000
Tumor Antigen Presentation By MicrogliaNational Cancer Institute1998–1999

Insurance Accepted

BCBS Alabama PPO
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
First Health PPO
Multiplan PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment